Robert Ferris, MD
Otolaryngology · Raleigh, NCNPI 1851364509
Payments from drug & device makers
Across 326 payments — averaging $7677.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$1.2M
- Merck$934K
- Hoffmann-la Roche Limited$78K
- Foundation Medicine, Inc.$62K
- Regeneron Healthcare Solutions, Inc.$44K
- Regeneron$31K
- plus $126K from 26 others
Across 3 payments — averaging $1833.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Foundation Medicine, Inc.$4K
- Regeneron$1K
What the payments were for
- Consulting fees$171,38466%
- Speaking & faculty fees$37,69315%
- Travel & lodging$41,85316%
- Food & beverage$6,8653%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 45 | $1,227,651 |
| Merck | 63 | $933,957 |
| Hoffmann-la Roche Limited | 14 | $78,072 |
| Foundation Medicine, Inc. | 47 | $62,000 |
| Regeneron Healthcare Solutions, Inc. | 27 | $44,421 |
| Regeneron | 38 | $31,158 |
| Genentech, Inc. | 5 | $18,597 |
| Pfizer | 8 | $18,597 |
| Merck Kgaa | 3 | $13,755 |
| Macrogenics, Inc. | 5 | $12,680 |
| GSK | 13 | $11,677 |
| F. Hoffmann-la Roche AG | 2 | $9,920 |
| Astrazeneca UK Limited | 10 | $9,889 |
| Eisai Inc. | 2 | $7,300 |
| Janssen Research & Development, LLC | 2 | $4,380 |
| Lilly USA, LLC | 1 | $3,942 |
| Coherus Oncology, Inc. | 5 | $2,820 |
| Sanofi | 1 | $2,480 |
| Novartis | 1 | $2,170 |
| EMD Serono, Inc. | 1 | $2,000 |
| Astrazeneca AB | 8 | $1,355 |
| Kowa Research Institute, Inc. | 1 | $1,240 |
| Seagen Inc. | 1 | $1,030 |
| AstraZeneca | 6 | $428 |
| Arcutis Biotherapeutics, Inc. | 4 | $369 |
| Johnson & Johnson(2 entities) | 3 | $270 |
| Journey Medical Corporation | 2 | $243 |
| Novocure Inc. | 1 | $140 |
| Bayer | 3 | $138 |
| Sun Pharmaceutical Industries Inc. | 1 | $106 |
| Janssen Scientific Affairs, LLC | 1 | $98 |
| Amgen | 2 | $91 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,502,977 in reported general payments places this provider in the 95th percentile of 362 otolaryngology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 22 | $170 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Raleigh
- Jeevan RamakrishnanRaleigh$12K
- Brett DorfmanRaleigh$6K
- Viraj PatelRaleigh$5K
- Nicolas George KatsantonisRaleigh$5K
- David JangDurham$1M
- Mark WeigelHuntersville$275K
- Stephen PottsWinston Salem$242K
- Adam ZanationHickory$227K
- Anne SelleckChapel Hill$165K
- Jonathan MossMatthews$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.